RJx-01

The organizations say this collaboration uses the strengths of both to create a cutting-edge platform designed to uncover new insights into drugs, diseases, and biological networks by systematically exploring hidden biological patterns. The new discovery tool, to be developed on SAS Viya, a robust cloud-native AI and data platform, will, they say, combine Rejuvenate Biomed’s clinically validated AI-driven drug discovery capabilities with SAS’s extensive AI expertise. This collaboration is promising to enhance the efficiency and effectiveness of drug repurposing efforts, particularly for age-related diseases. “Our partnership with SAS amplifies the core strengths of both our R&D teams,” said Dr Ann Beliën, founder and chief executive officer of Rejuvenate Biomed. “By embracing this partnership and leveraging the capabilities of SAS Viya, we expect to meaningfully de-risk and accelerate the development of our internal portfolio while enhancing our discovery platform and partnering capabilities.” The low-code tool is designed for ease of use, allowing bioscience researchers with limited coding experience to harness powerful analytics. It will also serve advanced computational biology teams by providing a foundation for developing sophisticated analytics models. The tool will utilize SAS Visual Analytics for creating comprehensive reports, enabling researchers to derive actionable insights from complex biomedical data. “Our collaboration with Rejuvenate Biomed places us at the forefront of AI in biomedical research, reinforcing our commitment to supporting cutting-edge applied AI and analytics through SAS Viya,” said Udo Sglavo, vice president of Applied AI and Modeling at SAS. googletag.cmd.push(function () { googletag.display('text-ad1'); }); “Rejuvenate Biomed’s endorsement of SAS Viya to further develop their unique and proprietary drug discovery engine is a testament to our commitment to being the premier provider of structured and scalable AI solutions that enhance data analysis efficiency and accelerate the entire drug development life cycle.” This partnership not only equips Rejuvenate Biomed with the tools to scale its drug discovery platform but also strengthens its capacity to provide third-party services and expand its drug development pipeline. By utilizing AI to uncover non-trivial and novel biological interactions, Rejuvenate Biomed aims to accelerate the identification of potential therapeutic candidates and advance their development. Rejuvenate Biomed is a clinical-stage biotechnology company focused on developing therapeutics targeting the root causes of age-related diseases. Using its AI-enabled in silico CombinAge and in vivo CelegAge platforms, the company has built a pipeline of unique combination drugs addressing various age-related conditions, including neuromuscular, musculoskeletal, metabolic, cardiovascular, nephrological, and neurodegenerative diseases. Its lead asset, RJx-01, is phase 2-ready and has shown significant potential in treating sarcopenia. Rejuvenate Biomed said its disease-agnostic drug discovery platforms will continue to generate insights for future therapeutics, driving pipeline growth and fostering potential partnerships. Based in Belgium, Rejuvenate Biomed the company says it is committed to promoting healthy aging and advancing the science of age-related disease treatment.

Rejuvenate Biomed to accelerate its drug development pipeline of assets for age-related diseases using jointly developed tools DIEPENBEEK, Belgium and CARY, N.C., Aug. 1, 2024 /PRNewswire/ -- Rejuvenate Biomed and SAS announced today a partnership to develop a user-friendly drug repurposing discovery tool for researchers and scientists to uncover medically relevant insights about drugs, diseases, and biological networks, through fast and systematic explorations of hidden biological patterns. The discovery tool will be developed on SAS® Viya®, a powerful cloud-native artificial intelligence (AI) and data platform. The partnership will unite Rejuvenate Biomed's clinically validated AI-driven drug discovery platform and end-to-end drug development proficiency with SAS' decades of AI expertise. Continue Reading Rejuvenate Biomed's drug discovery tool will be developed on SAS Viya, a powerful cloud-native AI & data platform. Post this The partnership unites Rejuvenate Biomed’s clinically validated AI-driven drug discovery platform and end-to-end drug development proficiency with SAS’ decades of AI expertise. The comprehensive low-code tool will take data from known biomedical relationships and use SAS-based analytics to implement algorithms to uncover non-trivial and novel biological interactions, tapping SAS Visual Analytics for report creation. Aimed at ease of use, the tool will cater to bioscience researchers with limited coding experience, while also serving as a foundation for advanced analytics model development for cutting-edge computational biology teams. In addition, the collaboration between the two companies equips Rejuvenate Biomed with the tools and technology necessary to further develop and scale up its drug discovery platform, third party services and drug development pipeline. "Our partnership with SAS amplifies the core strengths of both our R&D teams," Dr. Ann Beliën, Founder and Chief Executive Officer of Rejuvenate Biomed. "By embracing this partnership and leveraging the capabilities of SAS Viya, we expect to meaningfully de-risk and accelerate the development of our internal portfolio while enhancing our discovery platform and partnering capabilities." "Our collaboration with Rejuvenate Biomed places us at the forefront of AI in biomedical research, reinforcing our commitment to supporting cutting-edge applied AI and analytics through SAS Viya," said Udo Sglavo, Vice President of Applied AI and Modeling at SAS. "Rejuvenate Biomed's endorsement of SAS Viya to further develop their unique and proprietary drug discovery engine is a testament to our commitment to being the premier provider of structured and scalable AI solutions that enhance data analysis efficiency and accelerate the entire drug development life cycle." About Rejuvenate Biomed Rejuvenate Biomed is a clinical-stage biotechnology company developing therapeutics that target the root causes of age-related diseases. Utilizing two clinically validated proprietary drug discovery platforms, the AI-enabled in silico CombinAgeTM and in vivo CelegAgeTM, Rejuvenate Biomed has built a pipeline of five unique combination drugs targeting different age-related diseases, including neuromuscular, musculoskeletal, metabolic, cardiovascular, nephrological, and neurodegenerative indications. Its lead Phase 2-ready asset, RJx-01, has already demonstrated significant potential in treating sarcopenia. The company's disease agnostic drug discovery platforms continue to provide insight into future therapeutics, driving pipeline growth and potential partnerships. Based in Belgium, Rejuvenate Biomed is dedicated to promoting healthy aging. For more information, please visit or contact: [email protected] About SAS SAS is a global leader in data and AI. With SAS software and industry-specific solutions, organizations transform data into trusted decisions. SAS gives you THE POWER TO KNOW®. Rejuvenate Biomed Contacts Company contact [email protected] Media Contact Madelin Hawtin LifeSci Communications [email protected] SAS Contacts Jennifer James SAS Media Relations [email protected] SOURCE SAS